JG
NAVB

Jefferies Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Jefferies Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-124
Closed -$4K – 3417
2015
Q2 		$4K Buy
+124
New +$3.6K ﹤0.01% 3061
2015
Q1 		– Sell
-559
Closed -$21K – 2528
2014
Q4 		$21K Buy
+559
New +$15.4K ﹤0.01% 1870

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's NAVB Position: Q3 2015 in Review

Jefferies Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2015, closing a stake of 124 shares — an estimated $4K sold.

Jefferies Group first reported a position in NAVB in Q4 2014 and held it in 2 quarters. The position peaked at $21K in Q4 2014. 81 funds tracked by Wall St. Rank hold NAVB as of Q3 2015.

  • Jefferies Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2015 after selling out during the quarter.
  • Jefferies Group sold 124 Navidea Biopharmaceuticals Inc. shares in Q3 2015, an estimated $4K.
  • Jefferies Group first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 2 quarters.
  • Jefferies Group's Navidea Biopharmaceuticals Inc. position peaked at $21K in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2015.

Based on Jefferies Group's 13F filing for Q3 2015, filed 13 Nov 2015.